Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | CA9 | Q16790 | 1/20 | 0.42 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | FLT1 | P17948 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25898936 | 0.83 | ESRRA (0.48) | S1PR1NOTUM | |
| SCHEMBL22185933 | 0.81 | NOTUM (0.55) | CA12CA1CA2CA9TRPV1 | |
| SCHEMBL25494336 | 0.81 | NOTUM (0.42) | CA12CA1CA2CA9TRPV1 | |
| SCHEMBL25494321 | 0.81 | NOTUM (0.39) | CA12CA1CA2CA9TRPV1 | |
| SCHEMBL13160180 | 0.77 | NOTUM (0.51) | NOTUM | |
| SCHEMBL13183607 | 0.77 | NOTUM (0.53) | CA12CA1CA2CA9PTGS2 | |
| SCHEMBL9729936 | 0.76 | FLT3 (0.46) | CA1CA2CA9PTGS2NOTUM | |
| SCHEMBL13119830 | 0.75 | P2RX7 (0.50) | PTGS2NOTUM | |
| SCHEMBL19589440 | 0.74 | MAOA (0.50) | FLT1KDRNOTUM | |
| SCHEMBL24027315 | 0.74 | CA12 (0.48) | CA12CA1CA2CA9TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | LYCIA THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | LYCIA THERAPEUTICS, INC. | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158155-A1 | Cell Surface Receptor Binding Compounds and Conjugates | M6PR, ASGR1, IGF2R | CA12 1621/4885CA1 3431/4885CA2 3060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.